Following Bitcoin and Ethereum, ETF products for various altcoins, primarily XRP, have taken their place in the US market. As the altcoin ETF market continues to expand in the US, news has emerged for yet another altcoin.
Accordingly, Injective (INJ) co-founder and CEO Eric Chen stated that the launch of spot INJ ETFs in the US may not happen until 2027.
Chen’s statement has reignited expectations regarding ETF applications in the US that will follow INJ.
“2027 Might Be a Little Too Far Away!”
Speaking to The Block, Eric Chen avoided giving a specific date for when INJ ETFs in the US would begin trading. However, Chen stated that 2027 is a rather distant date for a spot INJ ETF in the US, suggesting that the ETF launch could happen sooner.
Chen said, “I can’t comment on a precise timeframe, but I think 2027 is a bit too far off. Actually, it’s much earlier than I expected, so we’ll see.”
Two ETF Applications on the Agenda!
Chen currently has two pending applications with the US SEC. The first is the 21Shares Injective ETF, and the second is the Canary Staked INJ ETF, which includes staking features.
21Shares filed Form S-1/A with the SEC in September 2026 regarding its ETF application. The application states that the fund’s primary objective is to track the price performance of INJ and that it plans to be listed on Nasdaq.
Canary Capital had already submitted its initial application for the INJ ETF, which will feature staking, in the US in 2025.
Injective Focuses on the Corporate Sector!
Chen’s ETF announcement comes as Injective expands its corporate reach in the U.S. Noting that Injective Institutional Services became a SEC-registered transfer agent in August, Chen stated that this is just the beginning and they will be working towards obtaining more licenses in the coming period.
Finally, Chen noted that Injective completed the notification and publication process of INJ’s MiCA technical document in July, and that INJ is now on the provisional register of the European Securities and Markets Authority (ESMA). He stated that this is a step towards INJ beginning to trade in the EU, adding that obtaining a license in the region is a slow process, which is why Injective works with firms that already have licenses.
